Logo Logo

Publications by Prada, Elke Tatjana Aristizabal

Up a level
Export as [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date
Number of items: 6.

Journal article

Reuther, Clemens; Heinzle, Vera; Noelting, Svenja; Herterich, Sabine; Hahner, Stefanie; Halilovic, Ensar; Jeay, Sebastien; Wuerthner, Jens U.; Prada, Elke Tatjana Aristizabal; Spoettl, Gerald; Maurer, Julian; Auernhamme, Christoph J. (2018): The HDM2 (MDM2) Inhibitor NVP-CGM097 Inhibits Tumor Cell Proliferation and Shows Additive Effects with 5-Fluorouracil on the p53-p21-Rb-E2F1 Cascade in the p53(wild type) Neuroendocrine Tumor Cell Line GOT1. In: Neuroendocrinology, Vol. 106, No. 1: pp. 1-19

Prada, Elke Tatjana Aristizabal; Noelting, Svenja; Spoettl, Gerald; Maurer, Julian; Auernhammer, Christoph Josef (2018): The Novel Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) Alone and in Dual-Targeting Approaches Demonstrates Antitumoral Efficacy in Neuroendocrine Tumors in vitro. In: Neuroendocrinology, Vol. 106, No. 1: pp. 58-73

Prada, Elke Tatjana Aristizabal; Heinzle, Vera; Knoesel, Thomas; Noelting, Svenja; Spoettl, Gerald; Maurer, Julian; Spitzweg, Christine; Angele, Martin; Schmidt, Nina; Beuschlein, Felix; Stalla, Guenter K.; Blaser, Rainer; Kuhn, Klaus A.; Auernhammer, Christoph J. (2018): Tropomyosin receptor kinase: a novel target in screened neuroendocrine tumors. In: Endocrine-Related Cancer, Vol. 25, No. 5: pp. 547-560

Nölting, Svenja; Rentsch, Jakob; Freitag, Helma; Detjen, Katharina; Briest, Franziska; Möbs, Markus; Weissmann, Victoria; Siegmund, Britta; Auernhammer, Christoph J.; Prada, Elke Tatjana Aristizabal; Lauseker, Michael; Grossman, Ashley; Exner, Samantha; Fischer, Christian; Schrader, Jörg; Grabowski, Patricia (2017): The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models.
In: PLoS ONE 12(8), e0182852 [PDF, 8MB]

Prada, Elke Tatjana Aristizabal; Orth, Michael; Nölting, Svenja; Spöttl, Gerald; Maurer, Julian; Auernhammer, Christoph (2017): The MTH1 inhibitor TH588 demonstrates anti-tumoral effects alone and in combination with everolimus, 5-FU and gamma-irradiation in neuroendocrine tumor cells.
In: PLOS One 12(5), e0178375 [PDF, 15MB]

Noelting, Svenja; Maurer, Julian; Spoettl, Gerald; Prada, Elke Tatjana Aristizabal; Reuther, Clemens; Young, Karen; Korbonits, Marta; Goeke, Burkhard; Grossman, Ashley; Auernhammer, Christoph J. (2015): Additive Anti-Tumor Effects of Lovastatin and Everolimus In Vitro through Simultaneous Inhibition of Signaling Pathways.
In: PLOS ONE 10(12), e0143830 [PDF, 3MB]

This list was generated on Sat May 30 00:21:36 2020 CEST.